Patents by Inventor Yaozhong Zou
Yaozhong Zou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230265498Abstract: A method for determining the type of a nucleotide on a nucleic acid sequence to be analyzed, and a nucleic acid sequencing method. In the method, at least one modified nucleotide for nucleic acid synthesis is separated from a nucleic acid sequence to be analyzed and other components on both sides of a membrane; when the modified nucleotide is transferred to the other side of the membrane under the action of an electric field by means of a nanopore embedded on the membrane, a synthesis reaction is conducted; moreover, the type of a base of the nucleotide is determined according to the change of the electrical properties of the nanopore in the process of the modified nucleotide is transferred by the nanopore, so as to implement sequencing.Type: ApplicationFiled: July 2, 2021Publication date: August 24, 2023Inventors: Yaozhong ZOU, Yunpeng SU, Ronghuo QIN, Peng JIANG, Jiazhi LIU
-
Publication number: 20230194499Abstract: Provided are a nanopore preparation and detection method and detection apparatus thereof. The method comprises: forming a nanopore by aggregating a plurality of protein monomers, with a signal detection region of the nanopore being formed in a narrow passage portion of the nanopore; and forming a positive charge cluster in the signal detection region of the nanopore, wherein the charge interaction between the positive charge cluster and negatively charged single molecule analytes that pass through the nanopore can lengthen the residence time of the single molecule analytes in the nanopore. Accordingly, the effective detection of analytes at a single-molecular level is realized, such that single molecule analytes that cannot generate an effective detection signal due to an interaction time with a. nanopore being too short can be effectively detected, the prevalence of single molecule analytes can be significantly improved, and different analytes and detection requirements are accommodated.Type: ApplicationFiled: April 14, 2021Publication date: June 22, 2023Inventors: Yaozhong ZOU, Yunpeng SU, Peng JIANG, Yan WANG, Yuqin LI
-
Patent number: 11150233Abstract: Described herein are nanopore protein conjugates that can be used in DNA sequencing reactions. The nanopore protein conjugates includes a nanopore protein monomer that is joined to a DNA binding domain. The nanopore protein monomer is available to oligomerize with other nanopore protein monomers, while the DNA binding domain is available to bind to a template DNA strand. In certain examples, the nanopore protein monomer is an alpha-hemolysin monomer or variant thereof and the DNA binding domain is an Sso7d protein or variant thereof, such as an Sso7d-like protein. Also provided are nanopore protein assemblies incorporating the nanopore protein conjugates, along with methods of using the nanopore protein assemblies in sequencing reactions.Type: GrantFiled: September 28, 2018Date of Patent: October 19, 2021Assignee: Roche Sequencing Solutions, Inc.Inventors: Timothy Craig, Corissa Harris, Matt Dipetro, Mark Ambroso, Yaozhong Zou, Marshall Porter, Issa Delkaninia, Alexxa Noble, James Fairman, Wiseley Wu, Kapil Bajaj, Giovanni Bellesia, Seong-Ho Shin
-
Publication number: 20210269870Abstract: Described herein are variants of alpha-hemolysin having at least one mutation, such as a mutation to a positive charge. In certain examples, the mutation is selected from V149K, E287R, H35G, T109K, P151K, K147N, E111N, M113A, or combinations thereof in the mature, wild-type alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having a decreased time-to-thread. The decreased time-to-thread, for example, increases DNA sequencing efficiency and accuracy.Type: ApplicationFiled: February 25, 2021Publication date: September 2, 2021Applicant: Roche Sequencing Solutions, Inc.Inventors: Timothy K. CRAIG, Mark R. AMBROSO, Corissa J. HARRIS, Matthew M. DIPIETRO, Yaozhong ZOU, Marshall W. PORTER
-
Patent number: 10968480Abstract: Described herein are variants of alpha-hemolysin having at least one mutation, such as a mutation to a positive charge. In certain examples, the mutation is selected from V149K, E287R, H35G, T109K, P151K, K147N, E111N, M113A, or combinations thereof in the mature, wild-type alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having a decreased time-to-thread. The decreased time-to-thread, for example, increases DNA sequencing efficiency and accuracy.Type: GrantFiled: May 29, 2019Date of Patent: April 6, 2021Assignee: Roche Sequencing Solutions, Inc.Inventors: Timothy K. Craig, Mark R. Ambroso, Corissa J. Harris, Matthew M. Dipietro, Yaozhong Zou, Marshall W. Porter
-
Publication number: 20190367975Abstract: Described herein are variants of alpha-hemolysin having at least one mutation, such as a mutation to a positive charge. In certain examples, the mutation is selected from V149K, E287R, H35G, T109K, P151K, K147N, E111N, M113A, or combinations thereof in the mature, wild-type alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having a decreased time-to-thread. The decreased time-to-thread, for example, increases DNA sequencing efficiency and accuracy.Type: ApplicationFiled: May 29, 2019Publication date: December 5, 2019Applicant: Roche Sequencing Solutions, Inc.Inventors: Timothy K. CRAIG, Mark R. AMBROSO, Corissa J. HARRIS, Matthew M. DIPIETRO, Yaozhong ZOU, Marshall W. PORTER
-
Patent number: 10351908Abstract: Described herein are variants of alpha-hemolysin having at least one mutation, such as a mutation to a positive charge. In certain examples, the mutation is selected from V149K, E287R, H35G, T109K, P151K, K147N, E111N, M113A, or combinations thereof in the mature, wild-type alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having a decreased time-to-thread. The decreased time-to-thread, for example, increases DNA sequencing efficiency and accuracy.Type: GrantFiled: April 20, 2017Date of Patent: July 16, 2019Assignee: ROCHE SEQUENCING SOLUTIONS, INC.Inventors: Timothy K. Craig, Mark R. Ambroso, Corissa J. Harris, Matthew M. Dipietro, Yaozhong Zou, Marshall W. Porter
-
Publication number: 20190079067Abstract: Described herein are nanopore protein conjugates that can be used in DNA sequencing reactions. The nanopore protein conjugates includes a nanopore protein monomer that is joined to a DNA binding domain. The nanopore protein monomer is available to oligomerize with other nanopore protein monomers, while the DNA binding domain is available to bind to a template DNA strand. In certain examples, the nanopore protein monomer is an alpha-hemolysin monomer or variant thereof and the DNA binding domain is an Sso7d protein or variant thereof, such as an Sso7d-like protein. Also provided are nanopore protein assemblies incorporating the nanopore protein conjugates, along with methods of using the nanopore protein assemblies in sequencing reactions.Type: ApplicationFiled: September 28, 2018Publication date: March 14, 2019Applicant: GENIA TECHNOLOGIES, INC.Inventors: Timothy Craig, Corissa Harris, Matt Dipetro, Mark Ambroso, Yaozhong Zou, Marshall Porter, Issa Delkaninia, Alexxa Noble, James Fairman, Wiseley Wu, Kapil Bajaj, Giovanni Bellesia, Seong-Ho Shin
-
Publication number: 20170306397Abstract: Described herein are variants of alpha-hemolysin having at least one mutation, such as a mutation to a positive charge. In certain examples, the mutation is selected from V149K, E287R, H35G, T109K, P151K, K147N, E111N, M113A, or combinations thereof in the mature, wild-type alpha-hemolysin amino acid sequence. The ?-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having a decreased time-to-thread. The decreased time-to-thread, for example, increases DNA sequencing efficiency and accuracy.Type: ApplicationFiled: April 20, 2017Publication date: October 26, 2017Inventors: Timothy K. CRAIG, Mark R. AMBROSO, Corissa J. HARRIS, Matthew M. DIPIETRO, Yaozhong ZOU, Marshall W. PORTER
-
Patent number: 9422359Abstract: Certain embodiments provide a GPCR fusion protein. In particular embodiments, the GPCR fusion protein comprises: a) a G-protein coupled receptor (GPCR); and b) an autonomously folding stable domain, where the autonomously folding stable domain is N-terminal to the GPCR and is heterologous to the GPCR. The GPCR fusion protein is characterized in that is crystallizable under lipidic cubic phase crystallization conditions. In certain embodiments, the GPCR fusion protein may be crystallizable in a complex with a G-protein or in a complex with an antibody that binds to the IC3 loop of the GPCR.Type: GrantFiled: May 16, 2014Date of Patent: August 23, 2016Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Brian K. Kobilka, Yaozhong Zou
-
Publication number: 20140303345Abstract: Certain embodiments provide a GPCR fusion protein. In particular embodiments, the GPCR fusion protein comprises: a) a G-protein coupled receptor (GPCR); and b) an autonomously folding stable domain, where the autonomously folding stable domain is N-terminal to the GPCR and is heterologous to the GPCR. The GPCR fusion protein is characterized in that is crystallizable under lipidic cubic phase crystallization conditions. In certain embodiments, the GPCR fusion protein may be crystallizable in a complex with a G-protein or in a complex with an antibody that binds to the IC3 loop of the GPCR.Type: ApplicationFiled: May 16, 2014Publication date: October 9, 2014Inventors: Brian K. Kobilka, Yaozhong Zou
-
Patent number: 8765414Abstract: Certain embodiments provide a GPCR fusion protein. In particular embodiments, the GPCR fusion protein comprises: a) a G-protein coupled receptor (GPCR); and b) an autonomously folding stable domain, where the autonomously folding stable domain is N-terminal to the GPCR and is heterologous to the GPCR. The GPCR fusion protein is characterized in that is crystallizable under lipidic cubic phase crystallization conditions. In certain embodiments, the GPCR fusion protein may be crystallizable in a complex with a G-protein or in a complex with an antibody that binds to the IC3 loop of the GPCR.Type: GrantFiled: March 14, 2012Date of Patent: July 1, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Brian K. Kobilka, Yaozhong Zou
-
Publication number: 20120237978Abstract: Certain embodiments provide a GPCR fusion protein. In particular embodiments, the GPCR fusion protein comprises: a) a G-protein coupled receptor (GPCR); and b) an autonomously folding stable domain, where the autonomously folding stable domain is N-terminal to the GPCR and is heterologous to the GPCR. The GPCR fusion protein is characterized in that is crystallizable under lipidic cubic phase crystallization conditions. In certain embodiments, the GPCR fusion protein may be crystallizable in a complex with a G-protein or in a complex with an antibody that binds to the IC3 loop of the GPCR.Type: ApplicationFiled: March 14, 2012Publication date: September 20, 2012Inventors: Brian K. Kobilka, Yaozhong Zou